Aarkstore -Interleukin-23 (IL-23) Inhibitors -Pipeline Insights, 2014

1
Interleukin-23 (IL-23) Inhibitors -Pipeline
Insights, 2014
Category Pharmaceuticals Healthcare

• Browse Complete Report -
• http//www.aarkstore.com/pharmaceuticals-healthcar
  e/75781/interleukin-23-il-23-inhibitors-pipeline-i
  nsights-2014

2
Summary

• DelveInsights,Interleukin-23 (IL-23)
  Inhibitors-Pipeline Insights, 2014, report
  provides comprehensive insights about pipeline
  drugs across this mechanism of action (MOA). A
  key objective of the report is to establish the
  understanding for all the pipeline drugs that
  fall under Interleukin-23 (IL-23) Inhibitors.
  This report provides information on the
  therapeutic development based on the
  Interleukin-23 (IL-23) Inhibitors dealing with
  mechanism of action, comparative analysis at
  various stages covering Filed, Phase III, Phase
  II, Phase I, IND filed, Preclinical, Discovery
  and unknown stages, therapeutics assessment by
  monotherapy and combination products and molecule
  type drug information. The report also covers the
  companies information involved in the therapeutic
  development of the products. It also has
  highlighted the discontinued and dormant products.

3
Summary

• Data Sources
• The report is built using data and information
  sourced from proprietary databases, primary and
  secondary research and in-house analysis by
  DelveInsight team of industry experts.Secondary
  sources information and data has been collected
  from various printable and non-printable sources
  like search engines, News websites, Government
  Websites, Trade Journals, White papers,
  Magazines, Trade associations, Books, Industry
  Portals, Industry Associations and access to
  available databases.Please note this report
  requires certain updates. We have all the
  information available but require 3 business days
  to complete the process and ensure it is as
  up-to-date as possible. Certain sections in the
  report may be removed or altered based on the
  availability and relevance of data for the
  indicated mechanism of action. 

4
Summary

• Scope 
• The report provides a snapshot of the global
  therapeutic landscape of Interleukin-23 (IL-23)
  InhibitorsThe report provides pipeline products
  under drug profile section which includes product
  description, MOA, licensors collaborators,
  development partner and chemical
  informationCoverage of the Interleukin-23
  (IL-23) Inhibitors pipeline on the basis of
  target, MOA, route of administration, technology
  involved and molecule typeThe report reviews key
  players involved in the therapeutics development
  for Interleukin-23 (IL-23) Inhibitors and also
  provide company profilingThe report also gives
  the information of dormant and discontinued
  pipeline projects Pipeline products coverage
  based on various stages of development ranging
  from preregistration till discovery and
  undisclosed stages Provides pipeline assessment
  by monotherapy and combination therapy products,
  stage of development and molecule type

5
Summary

• Reasons to buyComplete MOA intelligence and
  complete understanding over therapeutics
  development for Interleukin-23 (IL-23) Inhibitors
• Identify the relationship between the drugs and
  use it for target finding, drug repurposing, and
  precision medicine.
• Devise corrective measures for pipeline projects
  by understanding Interleukin-23 (IL-23)
  Inhibitors pipeline depth and focus of Indication
  therapeutics
• Developing strategic initiatives to support your
  drug development activities.
• Optimize your portfolio and keep you in touch
  with the rapidly changing pharmaceutical markets,
  and make the best decisions for your business.

6
Summary

• Develop and design in licensing and out licensing
  strategies by identifying prospective partners
  with the most attractive projects to enhance and
  expand business potential and Scope
• Provides strategically significant competitor
  information, analysis, and insights to formulate
  effective RD development strategies
• Modify the therapeutic portfolio by identifying
  discontinued projects and understanding the
  factors that drove them from pipeline
• Gaining a Full Picture of the Competitive
  Landscape for Evidence based Decisions

7
Table of Content

• Interleukin-23 (IL-23) Inhibitors Overview
• Interleukin-23 (IL-23) Inhibitors Disease
  Associated
• Interleukin-23 (IL-23) Inhibitors Pipeline
  Therapeutics
• Interleukin-23 (IL-23) Inhibitors Therapeutics
  under Development by Companies
• Interleukin-23 (IL-23) Inhibitors Late Stage
  Products (Filed and Phase III)
• Comparative Analysis
• Interleukin-23 (IL-23) Inhibitors Mid Clinical
  Stage Products (Phase II)
• Comparative Analysis
• Interleukin-23 (IL-23) Inhibitors Early Clinical
  Stage Products (Phase I and IND Filed)
• Comparative Analysis
• Interleukin-23 (IL-23) Inhibitors Discovery and
  Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles

8
Table of Content

• Interleukin-23 (IL-23) Inhibitors Therapeutics
  Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Interleukin-23 (IL-23) Inhibitors Discontinued
  Products
• Interleukin-23 (IL-23) Inhibitors Dormant
  Products
• Companies Involved in Therapeutics Development
  for Interleukin-23 (IL-23) Inhibitors
• Appendix
• Methodology
• Contact Us
• Disclaimer

9
List of Tables

• Number of Products under Development for
  Interleukin-23 (IL-23) Inhibitors by Therapy
  Area, 2014
• Number of Products under Development for
  Interleukin-23 (IL-23) Inhibitors, 2014
• Number of Products under Development by Companies
  
• Comparative Analysis by Late Clinical Stage
  Products (Filed and Phase III), 2014
• Comparative Analysis Mid Clinical Stage Products
  (Phase II), 2014
• Comparative Analysis Early Clinical Stage
  Products (Phase I and IND Filed), 2014
• Comparative Analysis Discovery and Pre-Clinical
  Stage Products, 2014
• Drug Candidates Profiles
• Interleukin-23 (IL-23) Inhibitors Assessment by
  Monotherapy Products

10
List of Tables

• Interleukin-23 (IL-23) Inhibitors Assessment by
  Combination Products
• Interleukin-23 (IL-23) Inhibitors Assessment by
  Route of Administration
• Interleukin-23 (IL-23) Inhibitors Assessment by
  Stage and Route of Administration
• Interleukin-23 (IL-23) Inhibitors Assessment by
  Molecule Type
• Interleukin-23 (IL-23) Inhibitors Assessment by
  Stage and Molecule Type
• Interleukin-23 (IL-23) Inhibitors Therapeutics
  Discontinued Products
• Interleukin-23 (IL-23) Inhibitors Therapeutics
  Dormant Products
• Products under Development by Companies, 2014

11
List of Figures

• Number of Products under Development for
  Interleukin-23 (IL-23) Inhibitors by Therapy
  Area, 2014
• Number of Products under Development for
  Interleukin-23 (IL-23) Inhibitors, 2014
• Late Clinical Stage Products (Filed and Phase
  III), 2014
• Mid Clinical Stage Products (Phase II), 2014
• Early Clinical Stage Products (Phase I and IND
  Filed), 2014
• Discovery and Pre-Clinical Stage Products, 2014
• Interleukin-23 (IL-23) Inhibitors Assessment by
  Monotherapy Products
• Interleukin-23 (IL-23) Inhibitors Assessment by
  Combination Products
• Interleukin-23 (IL-23) Inhibitors Assessment by
  Route of Administration
• Interleukin-23 (IL-23) Inhibitors Assessment by
  Stage and Route of Administration
• Interleukin-23 (IL-23) Inhibitors Assessment by
  Molecule Type
• Interleukin-23 (IL-23) Inhibitors Assessment by
  Stage and Molecule Type

12
Related Reports

• 2015 Worldwide Medical Laboratories
  Industry-Industry Market Report
• 2015 Worldwide Pharmaceutical Preparation Mfg.
  Industry-Industry Market Report
• OncoPlex Diagnostics - Pharmaceuticals
  Healthcare - Deals and Alliances Profile
• MetaStat, Inc. - Pharmaceuticals Healthcare -
  Deals and Alliances Profile
• Advanced Cell Diagnostics, Inc. - Pharmaceuticals
  Healthcare - Deals and Alliances Profile
• Ascension Health - Pharmaceuticals Healthcare -
  Deals and Alliances Profile
• Accretive Health, Inc. (ACHI) - Strategic SWOT
  Analysis Review
• Jazz Pharmaceuticals plc (JAZZ) - Financial and
  Strategic SWOT Analysis Review
• Pharmstandard (PHST) - Financial and Strategic
  SWOT Analysis Review
• GLG Life Tech Corporation (GLG) - Financial and
  Strategic SWOT Analysis Review

13

• Interleukin-23 (IL-23) Inhibitors -Pipeline
  Insights, 2014
• Published Dec. 2014 60 Pages
• DelveInsights,Interleukin-23 (IL-23)
  Inhibitors-Pipeline Insights, 2014, report
  provides comprehensive insights about pipeline
  drugs across this mechanism of action (MOA).
• 
  Price

Format Price
PDF 1250
Site Licence 2500
Enterprise Wide Licence 4000
14
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953

• You Can Visit http//www.aarkstore.com
• OR Mail us at contact_at_aarkstore.com
• Blog
• http//www.aarkstore.com/blog/
• Conference
• http//conference.aarkstore.com/
• News
• http//www.aarkstore.com/news